A selective novel low-molecular-weight inhibitor of IκB kinase-β (IKK-β) prevents pulmonary inflammation and shows broad anti-inflammatory activity

British Journal of Pharmacology

Volumn 145, Issue 2, 2005, Pages 178-192

  Ziegelbauer, Karl ^a,c   Gantner, Florian ^a,d   Lukacs, Nicholas W ^b   Berlin, Aaron ^b   Fuchikami, Kinji ^a,e   Niki, Toshiro ^a,f   Sakai, Katsuya ^a,g   Inbe, Hisayo ^a,h   Takeshita, Keisuke ^a,f   Ishimori, Mina ^a,i   Komura, Hiroshi ^a   Murata, Toshiki ^a,j   Lowinger, Timothy ^a,k   Bacon, Kevin B ^a  

^a BAYER YAKUHIN LTD   (Japan)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c BAYER PHARMA AG   (Germany)

^d ALTANA PHARMA AG   (Germany)

^e In Silico Sciences Inc   (Japan)

^f GalPharma Co Ltd   (Japan)

^g OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

ⁱ Takeda Pharmaceutical Co Ltd ^*  (Japan)

^j TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^k BAYER CORPORATION   (United States)

more..

Author keywords

Asthma; Inflammation; Lung; Protein kinases; Signal transduction; Transcription factors

Indexed keywords

ALLERGEN; ARACHIDONIC ACID; CARRAGEENAN; CELL ADHESION MOLECULE; CHEMOKINE; COMPOUND A; CYTOKINE; I KAPPA B KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; OVALBUMIN; PHORBOL ESTER; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTHMA; B LYMPHOCYTE; BRONCHITIS; BRONCHUS HYPERREACTIVITY; BRONCHUS MUCOSA; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EDEMA; FEMALE; HUMAN; HUMAN CELL; INFLAMMATORY CELL; INFLAMMATORY DISEASE; LUNG DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE; WEIGHT GAIN;

EID: 19944374141     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706176     Document Type: Article

References (60)

1. ADCOCK, I.M. & ITO, K. (2004). Steroid resistance in asthma: a major problem requiring novel solutions or a non-issue. Curr. Opin. Pharmacol., 4, 257-262.
2. BAEUERLE, P.A. & BAICHWAL, V.R. (1997). NF-kappa B as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv. Immunol., 65, 111-137.
3. BARNES, P.J. & ADCOCK, I.M. (1997). NF-kappa B: a pivotal role in asthma and a new target for therapy. Trends Pharmacol. Sci., 18, 46-50.
4. BAXTER, A., BROUGH, S., COOPER, A., FLOETTMANN, E., FOSTER, S., HARDING, C., KETTLE, J., MCINALLY, T., MARTIN, C., MOBBS, M., NEEDHAM, M., NEWHAM, P., PAINE, S., ST-GALLAY, S., SALTER, S., UNITT, J. & XUE, Y. (2004). Hit-to-lead studies: the discovery of potent, orally active, thiophenecarboxamide IKK-2 inhibitors. Bioorg. Med. Chem. Lett., 14, 2817-2822.
5. BEASLEY, R. (2002). The burden of asthma with specific reference to the United States. J. Allergy Clin. Immunol., 109 (Suppl), S482-S489.
6. BELVISI, M.G., WICKS, S.L., BATTRAM, C.H., BOTTOMS, S.E., REDFORD, J.E., WOODMAN, P., BROWN, T.J., WEBBER, S.E. & FOSTER, M.L. (2001). Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separation of transrepression from transactivation activity. J. Immunol., 166, 1975-1982.
7. BOOTHBY, M., MORA, A.L., ARONICA, M.A., YOUN, J., SHELLER, J.R., GOENKA, S. & STEPHENSON, L. (2001). IL-4 signaling, gene transcription regulation, and the control of effector T cells. Immunol. Res., 23, 179-191.
8. BURKE, J.R., PATTOLI, M.A., GREGOR, K.R., BRASSIL, P.J., MACMASTER, J.F., MCINTYRE, K.W., YANG, X., IOTZOVA, V.S., CLARKE, W., STRNAD, J., QIU, Y. & ZUSI, F.C. (2003). BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem., 278, 1256-1450.
9. CAMANDOLA, S., LEONARDUZZI, G., MUSSO, T., VARESIO, L., CARINI, R., SCAVAZZA, A., CHIARPOTTO, E., BAEUERLE, P.A. & POLI, G. (1996). Nuclear factor κB is activated by arachidonic acid but not by eicosapentaenoic acid. Biochem. Biophys. Res. Commun., 229, 643-647.
10. CAMPBELL, E.M., CHARO, I.F., KUNKEL, S.L., STRIETER, R.M., BORING, L., GOSLING, J. & LUKACS, N.W. (1999). Monocyte chemoattractant protein-1 mediates cockroach allergen-induced bronchial hyperreactivity in normal but not CCR2-/- mice: the role of mast cells. J. Immunol., 163, 2160-2167.
11. CAMPBELL, E.M., KUNKEL, S.L., STRIETER, R.M. & LUKACS, N.W. (1998). Temporal role of chemokines in a murine model of cockroach allergen-induced airway hyperreactivity and eosinophilia. J. Immunol., 161, 7047-7053.
12. CASTRO, A.C., DANG, L.C., SOUCY, F., GRENIER, L., MAZDIYASNI, H., HOTTELET, M., PARENT, L., PIEN, C, PALOMBELLA, V. & ADAMS, J. (2003). Novel IKK inhibitors: beta-carbolines. Bioorg. Med. Chem. Lett., 13, 2419-2422.
13. CHEN, L.W., EGAN, L., LI, Z.W., GRETEN, F.R., KAGNOFF, M.F. & KARIN, M. (2003). The two faces of IKK and NF-kappaB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion. Nat. Med., 9, 575-581.
14. CHRISTMAN, J.W., SADIKOT, R.T. & BLACKWELL, T.S. (2000). The role of nuclear factor-kappa B in pulmonary diseases. Chest, 117, 1482-1487.
15. D'ACQUISTO, F., IANARO, A., IALENTI, A., IUVONE, T., COLANTUONI, V. & CARNUCCIO, R. (1999). Activation of nuclear transcription factor kappaB in rat carrageenin-induced pleurisy. Eur. J. Pharmacol., 369, 233-236.
16. DAS, J., CHEN, CH., YANG, L., COHN, L., RAY, P. & RAY, A. (2001). A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat. Immunol., 2, 45-50.
17. DE BOSSCHER, K., VAN DEN BERGHE, W. & HAEGEMAN, G. (2003). The interplay between the glucocorticoid receptor and nuclear factor-kappa B or activator protein-1: molecular mechanisms for gene repression. Endocr. Rev., 24, 488-522.
18. DONOVAN, C.E., MARK, D.A., HE, H.Z., LIOU, H.C., KOBZIK, L., WANG, Y, DE SANCTIS, G.T., PERKINS, D.L. & FINN, P.W. (1999). NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J. Immunol., 163, 6827-6833.
19. ELLIOTT, P.J., PIEN, C.S., MCCORMACK, T.A., CHAPMAN, I.D. & ADAMS, J. (1999). Proteasome inhibition: a novel mechanism to combat asthma. J. Allergy Clin. Immunol., 104, 294-300.
20. GAGLIARDO, R., CHANEZ, P., MATHIEU, M., BRUNO, A., COSTANZO, G., GOUGAT, C., VACHIER, I., BOUSQUET, J., BONSIGNORE, G. & VIGNOLA, A.M. (2003). Persistent activation of nuclear factor-kappaB signaling pathway in severe uncontrolled asthma. Am. J. Respir. Crit. Care Med., 168, 1190-1198.
21. GLEICH, G.J. (2000). Mechanisms of eosinophil-associated inflammation. J. Allergy Clin. Immunol., 105, 651-663.
22. GOSH, S. & KARIN, M. (2002). Missing pieces in the NF-κB puzzle. Cell, 109, S81-S86.
23. HART, L.A., KRISHNAN, V.L., ADCOCK, I.M., BARNES, P.J. & CHUNG, K.F. (1998). Activation and localization of transcription factor, nuclear factor-kappaB, in asthma. Am. J. Respir. Crit. Care Med., 158, 1585-1592.
24. HECKMANN, A., WALTZINGER, C, JOLICOEUR, P., DREANO, M., KOSCO-VILBOIS, M.H. & SAGOT, Y. (2004). IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS. Am. J. Pathol., 164, 1253-1262.
25. HIDESHIMA, T., CHAUHAN, D., RICHARDSON, P., MITSIADES, C., MITSIADES, N., HAYASHI, T., MUNSHI, N., DANG, L., CASTRO, A., PALOMBELLA, V., ADAMS, J. & ANDERSON, K.C. (2002). NF-kappa B as a therapeutic target in multiple myeloma. J. Biol. Chem., 277, 16639-16647.
26. HU, Y.L., BAUD, V., DELHASE, M., ZHANG, P., DEERINCK, T., ELLISMAN, M., JOHNSON, R. & KARIN, M. (1999). Abnormal morphogenesis but intact IKK activation in mice lacking the IKK alpha subunit of I kappa B kinase. Science, 284, 316-320.
27. HU, Y.L., BAUD, V., OGA, T., KIM, K.I., YOSHIDA, K. & KARIN, M. (2001). IKK alpha controls formation of the epidermis independently of NF-kappa B. Nature, 410, 710-714.
28. INOUE, H. & TANABE, T. (1998). Transcriptional role of the nuclear factor kappa B site in the induction by lipopolysaccharide and suppression by dexamethasone of cyclooxygenase-2 in U937 cells. Biochem. Biophys. Res. Commun., 244, 143-148.
29. KARIN, M., YAMAMOTO, Y. & WANG, Q.M. (2004). The IKK NF-kappa B System: a treasure trove for drug development. Nat. Rev. Drug Discov., 3, 17-26.
30. KISHORE, N., SOMMERS, C., MATHIALAGAN, S., GUZOVA, J., YAO, M., HAUSER, S., HUYNH, K., BONAR, S., MIELKE, C., ALBEE, L., WEIER, R., GRANETO, M., HANAU, C., PERRY, T. & TRIPP, C.S. (2003). A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. J. Biol. Chem., 278, 32861-32871.
31. LEUNG, D.Y. & BLOOM, J.W. (2003). Update on glucocorticoid action and resistance. J. Allergy Clin. Immunol., 111, 3-22.
32. LI, J., PEET, G.W., PULLEN, S.S., SCHEMBRI-KING, J., WARREN, T.C., MARCU, K.B., KEHRY, M.R., BARTON, R. & JAKES, S. (1998). Recombinant I kappa B kinases alpha and beta are direct kinases of I kappa B alpha. J. Biol. Chem., 273, 30736-30741.
33. LI, Q.T., VAN ANTWERP, D., MERCURIO, F., LEE, K.F. & VERMA, I.M. (1999). Severe liver degeneration in mice lacking the I kappa B kinase 2 gene. Science, 284, 321-325.
34. LI, X., MASSA, P.E., HANIDU, A., PEET, G.W., ARO, P., SAVITT, A., MISCHE, S., LI, J. & MARCU, K.B. (2002). IKK alpha, IKK beta, and NEMO/IKK gamma are each required for the NF-kappa B-mediated inflammatory response program. J. Biol. Chem., 277, 45129-45140.
35. LI, Z.W., CHU, W., HU, Y., DELHASE, M., DEERINCK, T., ELLISMAN, M., JOHNSON, R. & KARIN, M. (1999). The IKK beta subunit of I kappa B kinase (IKK) is essential for nuclear factor kappa B activation and prevention of apoptosis. J. Exp. Med., 189, 1839-1845.
36. LI, Z.W., OMORI, S.A., LABUDA, T., KARIN, M. & RICKERT, R.C. (2003). IKK beta is required for peripheral B cell survival and proliferation. J. Immunol., 170, 4630-4637.
37. MACMASTER, J.F., DAMBACH, D.M., LEE, D.B., BERRY, K.K., QIU, Y., ZUSI, F.C. & BURKE, J.R. (2003). An inhibitor of IkappaB kinase, BMS-345541, blocks endothelial cell adhesion molecule expression and reduces the severity of dextran sulfate sodium-induced colitis in mice. Inflamm. Res., 52, 508-511.
38. MCINTYRE, K.W., SHUSTER, D.J., GILLOOLY, K.M., DAMBACH, D.M., PATTOLI, M.A., LU, P., ZHOU, X.D., QIU, Y., ZUSI, F.C. & BURKE, J.R. (2003). A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum., 48, 7652-2659
39. MULLER, J.R. & SIEBENLIST, U. (2003). Lymphotoxin beta receptor induces sequential activation of distinct NF-kappa B factors via separate signaling pathways. J. Biol. Chem., 278, 12006-12012.
40. MURATA, T., SHIMADA, M., KADONO, H., SAKAKIBARA, S., YOSHINO, T., MASUDA, T., SHIMAZAKI, M., SHINTANI, T., FUCHIKAMI, K., BACON, K.B., ZIEGELBAUER, K.B. & LOWINGER, T.B. (2004a). Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 2: improvement of in vitro activity. Bioorg. Med. Chem. Lett., 14, 4013-4017.
41. MURATA, T., SHIMADA, M., SAKAKIBARA, S., YOSHINO, T., KADONO, H., MASUDA, T., SHIMAZAKI, M., SHINTANI, T., FUCHIKAMI, K., SAKAI, K., INBE, H., TAKESHITA, K., NIKI, T., UMEDA, M., BACON, K.B., ZIEGELBAUER, K.B. & LOWINGER, T.B. (2003). Discovery of novel and selective IKK-serine-threonine protein kinase inhibitors. Bioorg. Med. Chem. Lett., 13, 913-918.
42. MURATA, T., SHIMADA, M., SAKAKIBARA, S., YOSHINO, T., MASUDA, T., SHINTANI, T., SATO, H., KORIYAMA, Y., FUKUSHIMA, K., NUNAMI, N., YAMAUCHI, M., FUCHIKAMI, K., KOMURA, H., WATANABE, A., ZIEGELBAUER, K.B., BACON, K.B. & LOWINGER, T.B. (2004b). Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. Bioorg. Med. Chem. Lett., 14, 4019-4022.
43. NEWTON, R., KUITERT, L.M., BERGMANN, M., ADCOCK, I.M. & BARNES, P.J. (1997). Evidence for involvement of NF-kappaB in the transcriptional control of COX-2 gene expression by IL-1beta. Biochem. Biophys. Res. Commun., 237, 28-32.
44. PASPARAKIS, M., SCHMIDT-SUPPRIAN, M. & RAJEWSKY, K. (2002). IkappaB kinase signaling is essential for maintenance of mature B cells. J. Exp. Med., 196, 743-752.
45. POYNTER, M.E., IRVIN, C.G. & JANSSEN-HEININGER, Y.M. (2002). Rapid activation of nuclear factor-kappaB in airway epithelium in a murine model of allergic airway inflammation. Am. J. Pathol., 160, 1325-1334.
46. PUIGNERO, V. & QUERALT, J. (1997). Effect of topically applied cyclooxygenase-2-selective inhibitors on arachidonic acid- and tetradecanoylphorbol acetate-induced dermal inflammation in the mouse. Inflammation, 21, 431-442.
47. ROTHWARF, D.M. & KARIN, M. (1999). The NF-kappa B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE, 5, RE1.
48. RUDOLPH, D., YEH, W.C., WAKEHAM, A., RUDOLPH, B., NALLAINATHAN, D., POTTER, J., ELIA, A.J. & MAK, T.W. (2000). Severe liver degeneration and lack of NF-kappa B activation in NEMO/IKK gamma-deficient mice. Genes Dev., 14, 854-862.
49. SALLUSTO, F. & LANZAVECCHIA, A. (1994). Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med., 17, 1109-1118.
50. SENFTLEBEN, U., CAO, Y., XIAO, G., GRETEN, F.R., KRAHN, G., BONIZZI, G., CHEN, Y., HU, Y., FONG, A., SUN, S.C. & KARIN, M. (2001). Activation by IKK alpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293, 1495-1499.
51. SIL, A.K., MAEDA, S., SANO, Y., ROOP, D.R. & KARIN, M. (2004). IkB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature, 442, 660-664.
52. STACEY, M.A., SUN, G., VASSALLI, G., MARINI, M., BELLINI, A. & MATTOLI, S (1997). The allergen Der p1 induces NF-kappaB activation through interference with IkappaB alpha function in asthmatic bronchial epithelial cells. Biochem. Biophys. Res. Commun., 236, 522-526.
53. TAKEDA, K., TAKEUCHI, O., TSUJIMURA, T., ITAMI, S., ADACHI, O., KAWAI, T., SANJO, H., YOSHIKAWA, K., TERADA, N. & AKIRA, S. (1999). Limb and skin abnormalities in mice lacking IKKalpha. Science, 284, 313-316.
54. TANAKA, M., FUENTES, M.E., YAMAGUCH, I.K., DURNIN, M.H., DALRYMPLE, S.A., HARDY, K.L. & GOEDDEL, D.V. (1999). Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity, 10, 421-429.
55. TEGEDER, L, NIEDERBERGER, E., SCHMIDT, R., KUNZ, S., GUHRING, H., RITZELER, O., MICHAELIS, M. & GEISSLINGER, G (2004). Specific inhibition of IkappaB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J. Neurosci., 24, 1637-1645.
56. TOWNSEND, R.M., POSTELNEK, J., SUSULIC, V., MCINTYRE, K.W., SHUSTER, D.J., QIU, Y., ZUSI, F.C. & BURKE, J.R. (2004). A highly selective inhibitor of IkappaB kinase, BMS-345541, augments graft survival mediated by suboptimal immunosuppression in a murine model of cardiac graft rejection. Transplantation, 77, 1090-1094.
57. VERMA, I.M., STEVENSON, J.K., SCHWARZ, E.M., VAN ANTWERP, D. & MIYAMOTO, S. (1995). Rel/Nf-Kappa B/I Kappa B family: intimate tales of association and dissociation. Genes Der., 9, 2723-2735.
58. WENZEL, S. (2003). Mechanisms of severe asthma. Clin. Exp. Allergy, 33, 1622-1628.
59. YAMAMOTO, Y. & GAYNOR, R.B. (2004). IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem. Sci., 29, 72-79.
60. YANG, L., COHN, L., ZHANG, D.H., HOMER, R., RAY, A. & RAY, P. (1998). Essential role of nuclear factor kappa B in the induction of eosinophilia in allergic airway inflammation. J. Exp. Med., 188, 1739-1750.